- Home
- CNA vs EXEL Comparison
CNA vs EXEL Comparison
Compare CNA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNA
- EXEL
- Stock Information
- Founded
- CNA 1853
- EXEL 1994
- Country
- CNA United States
- EXEL United States
- Employees
- CNA N/A
- EXEL N/A
- Industry
- CNA Property-Casualty Insurers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNA Finance
- EXEL Health Care
- Exchange
- CNA Nasdaq
- EXEL Nasdaq
- Market Cap
- CNA 12.3B
- EXEL 10.4B
- IPO Year
- CNA N/A
- EXEL 2000
- Fundamental
- Price
- CNA $44.21
- EXEL $38.12
- Analyst Decision
- CNA Hold
- EXEL Buy
- Analyst Count
- CNA 1
- EXEL 23
- Target Price
- CNA $53.00
- EXEL $44.10
- AVG Volume (30 Days)
- CNA 355.8K
- EXEL 3.0M
- Earning Date
- CNA 11-03-2025
- EXEL 11-04-2025
- Dividend Yield
- CNA 8.72%
- EXEL N/A
- EPS Growth
- CNA N/A
- EXEL 81.76
- EPS
- CNA 3.66
- EXEL 2.08
- Revenue
- CNA $14,850,000,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- CNA N/A
- EXEL $9.14
- Revenue Next Year
- CNA $21.34
- EXEL $12.51
- P/E Ratio
- CNA $12.04
- EXEL $18.32
- Revenue Growth
- CNA 5.41
- EXEL 10.73
- 52 Week Low
- CNA $43.29
- EXEL $31.90
- 52 Week High
- CNA $51.42
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CNA 35.65
- EXEL 46.88
- Support Level
- CNA $43.92
- EXEL $33.76
- Resistance Level
- CNA $45.00
- EXEL $40.63
- Average True Range (ATR)
- CNA 0.73
- EXEL 1.31
- MACD
- CNA -0.12
- EXEL 0.07
- Stochastic Oscillator
- CNA 9.73
- EXEL 63.54
About CNA CNA Financial Corporation
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.